Replies to post #196150 on Biotech Values

[DewDiligence]

COCP—Big News! Hep C drug selected and to start Phase 1 in 2016.

In other words, in 2019 or thereabouts, COCP’s non-nuke (CC-31244) might be able to be combined with one or two HCV drugs from other companies to form a treatment regimen. Not exactly an enticing business proposition!